Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%? Wall Street legend Paul Mampilly recently identified this as the stock of the century. Buying up a handful of shares of this small company now could change your life and even make you millions.

NASDAQ:ASND - Ascendis Pharma A/S Stock Price, Forecast & News

$139.90
+0.77 (+0.55 %)
(As of 01/22/2020 01:10 AM ET)
Today's Range
$138.72
Now: $139.90
$142.34
50-Day Range
$105.81
MA: $128.69
$140.95
52-Week Range
$66.11
Now: $139.90
$142.94
Volume104,725 shs
Average Volume230,863 shs
Market Capitalization$5.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.50 million
Book Value$7.87 per share

Profitability

Net Income$-153,650,000.00
Net Margins-789.80%

Miscellaneous

Employees216
Market Cap$5.89 billion
Next Earnings Date4/1/2020 (Estimated)
OptionableOptionable

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

This little-known smart chip is crucial for the new 5G networks. And with 1 billion 5G devices coming online within 4 years...the market is estimated to be worth $12.3 TRILLION! This just-released special report reveals urgent details.

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Monday, November, 18th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $0.78. The biotechnology company had revenue of $2.49 million for the quarter, compared to the consensus estimate of $1.88 million. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

8 Wall Street analysts have issued 12 month target prices for Ascendis Pharma A/S's stock. Their forecasts range from $139.00 to $186.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $158.00 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

What are Wall Street analysts saying about Ascendis Pharma A/S stock?

Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:
  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (11/22/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Ascendis Pharma (ASND) with an Overweight rating and 12-mo. PT of $102. Ascendis is a pro-drug platform company based in Denmark that focuses on endocrinology-based rare diseases. The company leverages its novel pro-drug platform, TransCon™ to improve & extend duration of de-risked clinical-stage drugs’s action in the body. The company has upcoming Ph3 in its lead asset TransCon hGH, for treating growth hormone, expected in 1Q. We remain confident in clinical success of TransCon hGH, which should drive a first leg of upside in 2019. We also think that investors will assign more credit to the platform, especially TransCon PTH with Ph2 data expected YE2019." (1/23/2019)

Has Ascendis Pharma A/S been receiving favorable news coverage?

News stories about ASND stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Ascendis Pharma A/S.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 2,130,000 shares, a decline of 9.4% from the November 28th total of 2,350,000 shares. Based on an average trading volume of 246,600 shares, the days-to-cover ratio is currently 8.6 days. Approximately 4.9% of the company's stock are sold short. View Ascendis Pharma A/S's Current Options Chain.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include Neurocrine Biosciences (NBIX), AbbVie (ABBV), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), InVitae (NVTA), ACADIA Pharmaceuticals (ACAD), Alexion Pharmaceuticals (ALXN), Amarin (AMRN) and Arrowhead Pharmaceuticals (ARWR).

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Henry James International Management Inc. (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Henry James International Management Inc..

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was purchased by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank .

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $139.90.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $5.89 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.View Additional Information About Ascendis Pharma A/S.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Quantitative Easing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel